Two benefit routes instead of one
California's newly signed SB1023 expands access to long-acting injectable HIV prevention through both medical and prescription-drug benefits. The Insurance Department says the law takes effect January 1, 2027, aiming to make care easier through community clinics and smaller providers.
The legislative text specifies FDA-approved, non-self-administered antiretroviral drugs, devices or products for HIV/AIDS prevention under policies issued, amended or renewed on or after January 1, 2027. That policy trigger matters: the headline is not a statement that every existing October claim is already handled under the new route.
Check the product and policy date
When the product is obtained through the prescription-drug benefit, the text requires dispensing and administration by a provider acting within the scope of a license. Having a pharmacy benefit is not the same as permission to self-administer a product that requires clinical care.
The change concerns access and benefit placement, not a promise that every product or service is free in every plan. Ask how the actual policy covers the prescribed product and provider. The department confirms signed status and timing; the legislative text supplies the specific dual-benefit framework. Neither substitutes for medical advice or an individual coverage determination.